Let’s Chat: Patient Submissions and Discussion

As part of patient advocacy, Save Your Skin Foundation is one of the few patient advocacy organizations that is approved to submit treatment recommendations to the CADTH Common Drug Review (CDR) and to  pan-Canadian Oncology Drug Review (pCODR) from the patient perspective. As an ongoing initiative, we will post these recommendations online.

Most recent treatment approval news and submissions:

Great news for skin cancer patients in Québec and Newfoundland: announcing the listing of Cotellic (Cobimetinib)

In Québec effective July 19, 2017:  read more here (Appendix IV – page 19) and in Newfoundland, effective June 2017:  read more here.

Patient Survey on New Therapy: Opdivo + Yervoy in combination, for treatment-naïve adult patients with advanced (unresectable or metastatic) melanoma, regardless of BRAF #OpdivoYervoy   Click HERE to read the Report, dated June 16, 2017

Alberta and Saskatchewan access to Opdivo is confirmed for Lung, Melanoma, and Renal Cell Carcinoma

pERC recommends reimbursement cobimetinib conditional on the cost-effectiveness being improved to an acceptable level. Follow the discussion on social media using hashtag #sysfCobiVemu

New Cancer Immunotherapy Indication for Canadian Patients with Untreated Metastatic Melanoma
KEYTRUDA® (pembrolizumab) received approval for the treatment of patients with unresectable or metastatic melanoma who have not received prior treatment with ipilimumab. KEYTRUDA is now the first and only anti-PD1 agent approved for first-line treatment regardless of BRAF mutation status.
Follow the discussion on our social media channels using the hashtag: #sysfKeytruda

Nivolumab (Opdivo) Notification to Implement Issued
Follow the discussion on our social media channels using the hashtag: #sysfNivo

New Targeted Therapy for Treatment of Serious Form of Skin Cancer Approved in Canada: CotellicTM in combination with Zelboraf® designed to inhibit cancer growth in metastatic melanoma
Follow the discussion on social media using hashtag #sysfCobiVemu

Cobimetinib (Cotellic) in combination with vemurafenib Submission
Follow the discussion on social media using hashtag #sysfCobiVemu

Immunotherapy a Hot Topic at ECC 2015 at Same Time That Canada Celebrates Milestone Approval of Immunotherapy Opdivo (nivolumab) for Treatment of Previously Untreated BRAF 4600 Wild-Type Metastatic Melanoma
Follow the discussion on our social media channels using the hashtag: #sysfNivo

Nivolumab (Opdivo) for Melanoma Submission
Follow the discussion on our social media channels using the hashtag: #sysfNivo

Yervoy (Ipilimumab) – First Line
Follow the discussion on our social media channels using the hashtag: #sysfYervoy
Two major milestones for ground breaking melanoma immunotherapies bring a hopeful beginning for 2015

Picato (Ingenol Mebutate) Submission
Follow the discussion on our social media channels using the hashtag: #sysfPicato

Proleukin (Aldeskeulin) Submission
Follow the discussion on our social media channels using the hashtag: #sysfProleukin

Tafinlar&Mekinist Combo Submission
Follow the discussion on our social media channels using the hashtag: #sysfTafinlarMekinist
Save Your Skin Foundation Announces pERC’s Recommendation to Fund Debrafenib (Tafinlar) plus Trametinib (Mekinist) in Canada for Metastatic Melanoma – July 7, 2015
Dabrafenib (Tafinlar) in combination with trametinib (Mekinist) for Metastatic Melanoma: Patients’ reaction about pERC’s Recommendation

Keytruda (pembrolizumab) Submission
Follow the discussion on our social media channels using the hashtag: #sysfKeytruda
Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment – June 8, 2015

Share and chat with other patients, family members and others concerned about melanoma and skin cancer through one of our social media channels